BIOSCIENCE firm Oxford Immunotec, which has developed a breakthrough test for TB, reported £21.2m revenue for the three months to September 30.

The 46 per cent increase compared to last year was partly due to higher sales in the USA and Asia.

Sales were also boosted by American-based firm Imugen, which Immunotec bought in July for £18m.

The Milton Park-based firm also acquired diagnostics lab Immunetics for £4.8m last month.

Immunotec chief executive Dr Peter Wrighton-Smith said: “Sales performance exceeded our expectations in our core tuberculosis business, with solid organic growth coming from the United States and Asia.”